肝细胞-话题@MedSci

#肝细胞#

513篇内容 | 2754人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1863559, encodeId=ea0e18635595b, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, objectType=article, longId=211519, objectId=7c45211519d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c45211519d9, replyNumber=0, likeNumber=79, createdTime=2021-07-14, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c45211519d9, moduleTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c45211519d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863639, encodeId=b9281863639a1, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, objectType=article, longId=293055, objectId=28ee293055ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ee293055ec, replyNumber=0, likeNumber=67, createdTime=2022-11-16, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ee293055ec, moduleTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ee293055ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863583, encodeId=2cbb186358384, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Hepatol Int: 前瞻性研究评估TACE单纯使用碘油对比TACE使用碘油联合可降解的淀粉微球(DSM)治疗肝细胞癌的疗效, objectType=article, longId=213475, objectId=ae672134e56d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae672134e56d, replyNumber=0, likeNumber=60, createdTime=2022-05-07, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae672134e56d, moduleTitle=Hepatol Int: 前瞻性研究评估TACE单纯使用碘油对比TACE使用碘油联合可降解的淀粉微球(DSM)治疗肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae672134e56d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863609, encodeId=325b186360967, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, objectType=article, longId=218274, objectId=25462182e412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25462182e412, replyNumber=0, likeNumber=93, createdTime=2021-12-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25462182e412, moduleTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25462182e412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863610, encodeId=ccae1863610e9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响, objectType=article, longId=218300, objectId=ec13218300e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec13218300e1, replyNumber=0, likeNumber=87, createdTime=2022-04-28, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec13218300e1, moduleTitle=Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec13218300e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863530, encodeId=2c2d18635303e, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌, objectType=article, longId=205576, objectId=70432055e6e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70432055e6e8, replyNumber=0, likeNumber=73, createdTime=2021-12-22, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70432055e6e8, moduleTitle=恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70432055e6e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863630, encodeId=08d818636308f, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Cancers：手术和射频消融（RFA）治疗乙肝相关肝细胞癌患者的疗效对比, objectType=article, longId=221582, objectId=504422158293, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=504422158293, replyNumber=0, likeNumber=76, createdTime=2022-09-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=504422158293, moduleTitle=Cancers：手术和射频消融（RFA）治疗乙肝相关肝细胞癌患者的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=504422158293)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863629, encodeId=54c61863629e5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, objectType=article, longId=221546, objectId=86b522154637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86b522154637, replyNumber=0, likeNumber=82, createdTime=2022-09-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86b522154637, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86b522154637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863620, encodeId=69a0186362053, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=62, createdTime=2022-08-21, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863575, encodeId=070d18635e5c2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Nat Commun：WSX1：肝细胞癌的新型肿瘤抑制因子, objectType=article, longId=212737, objectId=a7b3212e37d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7b3212e37d4, replyNumber=0, likeNumber=74, createdTime=2022-03-14, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7b3212e37d4, moduleTitle=Nat Commun：WSX1：肝细胞癌的新型肿瘤抑制因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7b3212e37d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863599, encodeId=63781863599e7, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=JGH: 术后连续三天使用抗生素可以降低乙型肝炎病毒相关肝细胞癌肝切除术后的感染率, objectType=article, longId=217284, objectId=264621e284a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=264621e284a4, replyNumber=0, likeNumber=65, createdTime=2022-03-20, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=264621e284a4, moduleTitle=JGH: 术后连续三天使用抗生素可以降低乙型肝炎病毒相关肝细胞癌肝切除术后的感染率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=264621e284a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863576, encodeId=859518635e6f2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Brit J Cancer：中性粒细胞与淋巴细胞比值对肝细胞癌患者预后和诊断的意义, objectType=article, longId=212744, objectId=8099212e44e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8099212e44e6, replyNumber=0, likeNumber=64, createdTime=2021-08-25, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8099212e44e6, moduleTitle=Brit J Cancer：中性粒细胞与淋巴细胞比值对肝细胞癌患者预后和诊断的意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8099212e44e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863543, encodeId=4835186354328, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Int：慢性肝病肝细胞癌晚期复发的病理预测因素, objectType=article, longId=207805, objectId=286920e80512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286920e80512, replyNumber=0, likeNumber=0, createdTime=2021-09-02, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286920e80512, moduleTitle=Liver Int：慢性肝病肝细胞癌晚期复发的病理预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286920e80512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863600, encodeId=1b8b18636004d, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cnacer：BCLC 0/A期肝细胞癌根治性切除术后使用富马酸替诺福韦酯(TDF)预防复发优于恩替卡韦（ETV）, objectType=article, longId=217476, objectId=486321e47658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486321e47658, replyNumber=0, likeNumber=58, createdTime=2022-04-12, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486321e47658, moduleTitle=Liver Cnacer：BCLC 0/A期肝细胞癌根治性切除术后使用富马酸替诺福韦酯(TDF)预防复发优于恩替卡韦（ETV）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486321e47658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863613, encodeId=b8d2186361311, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, objectType=article, longId=219167, objectId=456221916eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456221916eb9, replyNumber=0, likeNumber=73, createdTime=2022-04-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456221916eb9, moduleTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456221916eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863531, encodeId=b142186353137, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？, objectType=article, longId=205664, objectId=7fb72056643d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb72056643d, replyNumber=0, likeNumber=62, createdTime=2021-12-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb72056643d, moduleTitle=Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb72056643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863568, encodeId=6848186356814, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=J Gastroenterology H：乐伐替尼能够降低晚期肝细胞癌患者疾病进展风险, objectType=article, longId=212078, objectId=38082120e85d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38082120e85d, replyNumber=0, likeNumber=0, createdTime=2021-11-13, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38082120e85d, moduleTitle=J Gastroenterology H：乐伐替尼能够降低晚期肝细胞癌患者疾病进展风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38082120e85d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863616, encodeId=3c461863616c3, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, objectType=article, longId=219316, objectId=14432193166f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14432193166f, replyNumber=0, likeNumber=80, createdTime=2022-06-10, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14432193166f, moduleTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14432193166f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863574, encodeId=33e618635e43d, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！, objectType=article, longId=212517, objectId=e01721251ecb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01721251ecb, replyNumber=0, likeNumber=76, createdTime=2021-08-10, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01721251ecb, moduleTitle=共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01721251ecb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1863580, encodeId=eef71863580c0, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, objectType=article, longId=213115, objectId=9d6a213115e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6a213115e4, replyNumber=0, likeNumber=63, createdTime=2021-09-03, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6a213115e4, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6a213115e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝细胞

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性

2021-07-14

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后

2022-11-16

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Hepatol Int: 前瞻性研究评估TACE单纯使用碘油对比TACE使用碘油联合可降解的淀粉微球(DSM)治疗肝细胞癌的疗效

2022-05-07

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性

2021-12-09

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响

2022-04-28

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌

2021-12-22

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Cancers：手术和射频消融（RFA）治疗乙肝相关肝细胞癌患者的疗效对比

2022-09-24

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL

2022-09-09

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2022-08-21

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Nat Commun：WSX1：肝细胞癌的新型肿瘤抑制因子

2022-03-14

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

JGH: 术后连续三天使用抗生素可以降低乙型肝炎病毒相关肝细胞癌肝切除术后的感染率

2022-03-20

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Brit J Cancer：中性粒细胞与淋巴细胞比值对肝细胞癌患者预后和诊断的意义

2021-08-25

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Int：慢性肝病肝细胞癌晚期复发的病理预测因素

2021-09-02

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cnacer：BCLC 0/A期肝细胞癌根治性切除术后使用富马酸替诺福韦酯(TDF)预防复发优于恩替卡韦（ETV）

2022-04-12

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗

2022-04-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？

2021-12-19

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

J Gastroenterology H：乐伐替尼能够降低晚期肝细胞癌患者疾病进展风险

2021-11-13

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析

2022-06-10

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！

2021-08-10

xjy02 (审核中...)

前往app查看评论内容

#肝细胞#

Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果

2021-09-03

科室
- - 订阅+
  - 更多科室
工具
服务